


Thalidomide-O-amido-C3-PEG3-C1-NH2

Cat. No.:	HY-131646
CAS No.:	1799711-29-7
Molecular Formula:	C ₂₇ H ₃₅ F ₃ N ₄ O ₁₁
Molecular Weight:	648.58
Target:	E3 Ligase Ligand-Linker Conjugates
Pathway:	PROTAC
Storage:	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 200 mg/mL (308.37 mM; Need ultrasonic)
 H₂O : ≥ 100 mg/mL (154.18 mM)
 * "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	1.5418 mL	7.7091 mL	15.4183 mL
	5 mM	0.3084 mL	1.5418 mL	3.0837 mL
	10 mM	0.1542 mL	0.7709 mL	1.5418 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 5 mg/mL (7.71 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 5 mg/mL (7.71 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 5 mg/mL (7.71 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Thalidomide-O-amido-C3-PEG3-C1-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology.

IC₅₀ & Target

Cereblon

REFERENCES

[1]. Lohbeck J, et al. Practical synthesis of a phthalimide-based Cereblon ligand to enable PROTAC development. *Bioorg Med Chem Lett*. 2016;26(21):5260-5262.
doi:10.1016/j.bmcl.2016.09.048

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA